

Merck Statement Against Ivermectin Exposing 'Big Pharma' Lobbyists

By Swiss Policy Research

Global Research, February 08, 2021

Swiss Policy Research 7 February 2021

Theme: <u>Science and Medicine</u>

All Global Research articles can be read in 27 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

A positive aspect of the recent anti-ivermectin statement by Merck is that dozens of 'big pharma' lobbyists, who immediately <u>shared the statement on Twitter</u>, are now getting exposed, among them many journalists, a US NIH representative, some industry-linked professors, and one of the most influential German government <u>'covid science communicators'</u>.

Merck,maker of Ivermectin in the US in an official statement today: No base for potential effect; Concerning side effect ... I doubt that this would impact the pretentious superstitious mind set but worth putting out in Respect to Rationality! https://t.co/3nE9JVWdfx pic.twitter.com/m5S0yTJ0MM

— Eid Azar (@EidAzar) February 5, 2021

Merck hat eine Stellungnahme zu Ivermectin als Therapie bei COVID19 veröffentlicht. Hierzu gibt es in den Social Media immer wieder "Werbung".Merck.com https://t.co/8vsdaoFyug

— Sandra Ciesek (@CiesekSandra) February 6, 2021

Keep in mind that Merck provided no evidence, whatsoever, for any of its claims, did not refute any of the existing evidence, studies and <u>meta-studies</u>, and falsely claimed 'unproven safety'. The entire statement is a desperate <u>appeal to (supposed) authority</u>, and anyone pushing it is simply exposing themselves as a lobbyist not interested in actual evidence-based medicine.

What Merck could have done, but didn't do, since April 2020, is running and publishing its own ivermectin trial. What Merck also could have done, but didn't do, is disclosing in its statement that it recently signed a \$356 million deal to supply the US with a much more expensive, newly developed experimental anti-covid drug. But doing this may not have been in Merck's interest, of course.

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is <u>Swiss Policy Research</u> Copyright © <u>Swiss Policy Research</u>, <u>Swiss Policy Research</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Swiss Policy

Research

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca